MarketCap
Facebook
X
Telegram
Country |
 USA |
IPO year |
2018 |
Industry |
Biotechnology |
Stock Exchange |
NYSE AMERICAN |
Shares |
10.2 M |
Market Cap[1] |
$ 12.2 K |
EBITDA (LTM) |
$ -23.9 M |
P/E (LTM) |
- |
P/S (LTM) |
0.093792 |
EPS (LTM) |
-1.91 |
Other stocks of industry "Biotechnology"
| Issuer | Price | % 24h | Market Cap | Exchange | Country | |
|---|---|---|---|---|---|---|
 |
Sigilon Therapeutics
SGTX
|
- | - | $ 728 M | Nasdaq Global Select Market | USA |
 |
Rubius Therapeutics
RUBY
|
- | -33.55 % | $ 7.81 M | Nasdaq Global Select Market | USA |
 |
Aptinyx
APTX
|
- | -39.0 % | $ 4.57 M | Nasdaq Global Select Market | USA |
 |
TRACON Pharmaceuticals
TCON
|
- | -1.38 % | $ 46.8 M | Nasdaq Capital Market | USA |
 |
Mirati Therapeutics
MRTX
|
- | - | $ 3.3 B | Nasdaq Global Select Market,SPB | USA |
 |
Revance Therapeutics
RVNC
|
- | - | $ 309 M | Nasdaq Global Select Market | USA |
 |
Allogene Therapeutics
ALLO
|
$ 1.09 | -8.82 % | $ 240 M | Nasdaq Global Select Market,SPB | USA |
 |
InVivo Therapeutics Holdings Corp.
NVIV
|
- | -37.48 % | $ 476 K | Nasdaq Capital Market | USA |
 |
Epizyme
EPZM
|
- | - | $ 249 M | Nasdaq Global Select Market | USA |
 |
Bellicum Pharmaceuticals
BLCM
|
- | -9.72 % | $ 5.89 M | Nasdaq Capital Market | USA |
 |
Processa Pharmaceuticals
PCSA
|
$ 1.86 | -4.07 % | $ 2.44 M | Nasdaq Global Select Market | USA |
 |
Forward Pharma A/S
FWP
|
- | -0.75 % | $ 18.7 M | Nasdaq Capital Market |  Danmark |
 |
Orchard Therapeutics plc
ORTX
|
- | 1.02 % | $ 90.8 M | Nasdaq Global Select Market |  Britain |
 |
La Jolla Pharmaceutical Company
LJPC
|
- | - | $ 154 M | Nasdaq Capital Market | USA |
 |
Oyster Point Pharma
OYST
|
- | - | $ 300 M | Nasdaq Global Select Market | USA |
 |
Nabriva Therapeutics plc
NBRV
|
- | - | $ 4.55 M | Nasdaq Global Select Market |  Irlanda |
 |
Intercept Pharmaceuticals
ICPT
|
- | - | $ 643 M | Nasdaq Global Select Market,SPB | USA |
 |
NGM Biopharmaceuticals
NGM
|
- | - | $ 127 M | Nasdaq Global Select Market,SPB | USA |
 |
Regulus Therapeutics
RGLS
|
- | - | $ 155 M | Nasdaq Global Select Market | USA |
 |
9 Meters Biopharma
NMTR
|
- | -42.97 % | $ 1.05 M | Nasdaq Global Select Market | USA |
 |
Chinook Therapeutics
KDNY
|
- | - | $ 2.6 B | Nasdaq Global Select Market | USA |
 |
Lumos Pharma
LUMO
|
- | - | $ 35.3 M | Nasdaq Global Select Market | USA |
 |
Syros Pharmaceuticals
SYRS
|
- | -8.44 % | $ 3.4 M | Nasdaq Global Select Market | USA |
 |
Gamida Cell Ltd.
GMDA
|
- | -18.25 % | $ 5.04 M | Nasdaq Global Market |  Israel |
 |
GT Biopharma
GTBP
|
$ 4.5 | -7.02 % | $ 24.8 M | Nasdaq Capital Market | USA |
 |
Aravive
ARAV
|
- | -13.39 % | $ 1.45 M | Nasdaq Global Select Market | USA |
 |
Bellerophon Therapeutics
BLPH
|
- | -74.18 % | $ 955 K | Nasdaq Capital Market | USA |
 |
C4 Therapeutics
CCCC
|
$ 2.96 | -5.29 % | $ 245 M | Nasdaq Global Select Market | USA |
 |
Regeneron Pharmaceuticals
REGN
|
$ 904.05 | -2.86 % | $ 94.6 B | Nasdaq Global Select Market,SPB | USA |
 |
Codexis
CDXS
|
$ 1.02 | -5.56 % | $ 88.9 M | Nasdaq Global Select Market | USA |
 |
Celldex Therapeutics
CLDX
|
$ 28.24 | -5.65 % | $ 1.88 B | Nasdaq Global Select Market | USA |
 |
CorMedix
CRMD
|
$ 5.23 | -7.69 % | $ 377 K | Nasdaq Global Market | USA |
 |
CRISPR Therapeutics AG
CRSP
|
$ 48.49 | -6.34 % | $ 4.36 B | Nasdaq Global Market,SPB |  Schweiz |
 |
SIGA Technologies
SIGA
|
$ 2.98 | -5.56 % | $ 213 M | Nasdaq Global Select Market | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
- | -1.52 % | $ 24.7 M | Nasdaq Capital Market | USA |
 |
Curis
CRIS
|
$ 0.84 | -24.32 % | $ 11.1 M | Nasdaq Global Market | USA |
|
Champions Oncology
CSBR
|
$ 4.79 | -0.83 % | $ 66.3 M | Nasdaq Capital Market | USA |
 |
Cytokinetics, Incorporated
CYTK
|
$ 54.5 | -14.31 % | $ 6.55 M | Nasdaq Global Select Market,SPB | USA |
 |
DiaMedica Therapeutics
DMAC
|
$ 9.03 | -16.16 % | $ 424 M | Nasdaq Capital Market | USA |
 |
Edesa Biotech
EDSA
|
$ 2.14 | -1.38 % | $ 12.1 M | Nasdaq Capital Market | USA |
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
$ 13.88 | -8.86 % | $ 898 M | NYSE | USA |
 |
Evogene Ltd.
EVGN
|
$ 0.32 | -9.87 % | $ 2.52 M | Nasdaq Global Market | Israel |
 |
Exelixis
EXEL
|
$ 68.71 | -5.56 % | $ 18.7 B | Nasdaq Global Select Market,SPB | USA |
 |
Xeris Pharmaceuticals
XERS
|
$ 13.16 | 25.76 % | $ 2.11 B | Nasdaq Global Select Market | USA |
 |
Fennec Pharmaceuticals
FENC
|
$ 9.35 | -9.66 % | $ 267 M | Nasdaq Capital Market | USA |
 |
AbbVie
ABBV
|
$ 288.16 | -2.26 % | $ 510 B | NYSE,SPB | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
$ 1.58 | -5.39 % | $ 2.6 M | NYSE American | Israel |
 |
vTv Therapeutics
VTVT
|
$ 21.86 | -9.03 % | $ 86.4 M | Nasdaq Global Select Market | USA |
|
Forte Biosciences
FBRX
|
$ 76.99 | 0.03 % | $ 997 M | Nasdaq Capital Market | USA |
 |
AC Immune SA
ACIU
|
$ 2.11 | -7.86 % | $ 213 M | Nasdaq Global Market | Schweiz |
References
- Pavone, P. (2019). Market capitalization and financial variables: Evidence from Italian listed companies. International Journal of Academic Research Business and Social Sciences, 9(3), 1356-1371.